BioMosaics Logo

The significance of glypican-3 expression profiling...

... in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.

Ran Xue et al.

Hepataology   First published: ; DOI: 10.1111/jgh.13736

Background and Aim

Glypican-3 (GPC3) expression is correlated with poor prognosis and progression in hepatocellular carcinoma (HCC). HCC progression can be associated with the differentiation status of tumor cell before malignant transformation. Our aim was to investigate the dynamic expression of GPC3 during tumor cells differentiation and to explore the role and theoretical significance of GPC3 in malignant essence of HCC.

Methods

The expressions of tissue GPC3 and alpha fetoprotein (AFP) were detected by immunohistochemical staining.

Continue Reading

Glycosaminoglycans are involved in bacterial adherence to lung cells.

BMC Infect Dis. 2017 May 2;17(1):319. doi: 10.1186/s12879-017-2418-5.

Glycosaminoglycans are involved in bacterial adherence to lung cells.

Rajas O, Quirós LM, Ortega M, Vazquez-Espinosa E, Merayo-Lloves J, Vazquez F, García B.

BACKGROUND:

Lower respiratory infections are among the top ten causes of death worldwide. Since pathogen to cell adhesion is a crucial step in the infection progress, blocking the interaction between eukaryotic receptors and bacterial ligands may enable the pathogenesis process to be stopped. Cell surface glycosaminoglycans (GAGs) are known to be mediators in the adhesion of diverse bacteria to different cell types, making it of interest to examine their involvement in the attachment of various pathogenic bacteria to lung cells, including epithelial cells and fibroblasts.

Continue Reading

Prediction of early HCC recurrence

Oncotarget. 2017 Jun 28. doi: 10.18632/oncotarget.18799. [Epub ahead of print]

Prediction of early recurrence of hepatocellular carcinoma within the Milan criteria after radical resection.

Feng J, Chen J, Zhu R, Yu L, Zhang Y, Feng D, Kong H, Song C, Xia H, Wu J, Zhao D.

Abstract

Approximately 50% hepatocellular carcinoma patients meeting the Milan criteria utilized to develop an improved prognostic model for predicting the recurrence in these patients. Using univariate and multivariate analysis, cytokeratin-19 and glypican-3 expression patterns, tumor number and histological grading from eight putative prognostic factors comprised the risk factor scoring model to predict the tumor recurrence. In the training cohort, the area under roc curve (AUC) value of the model was 0.715 [95% confidence interval (CI) = 0.645-0.786, P<0.001], which was the highest among all the parameters. The performance of the model was assessed using an independent validation cohort, wherein the AUC value was 0.760 (95% CI=0.647-0.874, P<0.001), which was higher than the other factors. The results indicated that model had high performance with adequate discrimination ability. Moreover, it significantly improved the predictive capacity for the recurrence in patients with hepatocellular carcinoma within the Milan criteria after radical resection.

Tissue Biomarkers in Hepatocellular Tumors: Which, When, and How

An excellent oveview of hepatocellular carcinoma histopathology from Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
 
Front Med (Lausanne). 2017; 4: 10.
Published online 2017 Feb 23. doi:  10.3389/fmed.2017.00010
Luca Di Tommaso and Massimo Roncalli
 

Abstract

Few tissue markers are currently available to pathologists in the study of hepatocellular tumors. These markers should be used carefully taking into consideration not only morphology but also, and sometimes even more important, the clinical setting where the lesion to be diagnosed had developed. Glypican-3, heat shock protein 70, and glutamine synthetase (GS) are markers currently used...

Continue Reading

GPC3 in odontogenic tumors

Glypican-3 distinguishes aggressive from non-aggressive odontogenic tumors: a preliminary study.

Mendes RB, Dias RB, et al., Dos Santos JN

BACKGROUND:

Glypican-3 is a cell surface proteoglycan that is found in embrionary tissues, and there are no studies investigating this protein in odontogenic tumor. Thus, the aim of this study was to investigate glypican-3 in a series of aggressive and non-aggressive odontogenic tumors.

METHODS:

Fifty-nine cases of tumors were divided into aggressive odontogenic tumors (20 solid ameloblastomas, four unicystic ameloblastoma, 28 KOTs including five associated with Gorlin-Goltz syndrome) and non-aggressive odontogenic tumors....

Continue Reading

Expression of PAX8 Target Genes...

...in Papillary Thyroid Carcinoma.

PLoS One. 2016 Jun 1;11(6):e0156658. doi: 10.1371/journal.pone.0156658. eCollection 2016.
Rosignolo F, Sponziello M, Durante C, Puppin C, Mio C, Baldan F, Di Loreto C, Russo D, Filetti S, Damante G.
Link to PuMed
Abstract

PAX8 is a thyroid-specific transcription factor whose expression is dysregulated in thyroid cancer. A recent study using a conditional knock-out mouse model identified 58 putative PAX8 target genes. In the present study, we evaluated the expression of 11 of these genes in normal and tumoral thyroid tissues from patients with papillary thyroid cancer (PTC).

Continue Reading

Modeling of Hepatocytes Proliferation...

...Isolated from Proximal and Distal Zones from Human Hepatocellular Carcinoma Lesion.
Montalbano M, Curcurù G, Shirafkan A, Vento R, Rastellini C, Cicalese L.

Abstract

Isolation of hepatocytes from cirrhotic human livers and subsequent primary culture are important new tools for laboratory research and cell-based therapeutics in the study of hepatocellular carcinoma (HCC). Using such techniques, we have previously identified different subpopulations of human hepatocytes and among them one is showing a progressive transformation of hepatocytes in HCC-like cells. We have hypothesized that increasing the distance from the neoplastic lesion might affect hepatocyte function and transformation capacity.

Continue Reading

Randomized Phase II placebo controlled study...

...of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.
Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, et al.
LInk to PubMed
PURPOSE:

Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3) that is expressed in HCC, interacts with CD16/ FcγRIIIa and triggers antibody-dependent cytotoxicity. Codrituzumab was studied versus placebo in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy.

Continue Reading

CK19 and Glypican 3 Expression...

...Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.

PLoS One. 2016 Mar 15;11(3):e0151501. doi: 10.1371/journal.pone.0151501. eCollection 2016.                    plosone.org images pone 120x30
Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G, Chen F, Xia H, Lv F, Zhang S, Sun L.
Abstract

This retrospective study was designed to investigate the correlation between a novel immunosubtyping method for hepatocellular carcinoma (HCC) and biological behavior of tumor cells. A series of 346 patients, who received hepatectomy at two surgical centers from January 2007 to October 2010, were enrolled in this study. The expressions of cytokeratin 19 (CK19), glypican 3 (GPC3), and CD34 were detected by immunohistochemical staining. The clinical stage was assessed using the sixth edition tumor-node-metastasis (TNM) system (UICC/AJCC, 2010).

Continue Reading

A New Cell Block Method...

...for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.

Cancer Res Treat. 2016 Mar 30. doi: 10.4143/crt.2015.500.
Nam SJ, Yeo HY, Chang HJ, Kim BH, Hong EK, Park JW.                                                     e crt.org image pubmed linkout banner
Purpose:

We developed a new method of detecting CTCs in liver cancer patients by constructing cell blocks from peripheral blood cells, including CTCs, followed by multiple immunohistochemical analysis.

Materials and Methods:

Cell blocks were constructed from the nucleated cell pellets of peripheral blood after removal of red blood cells. The blood cell blocks were obtained from 29 patients with liver cancer, and from healthy donor blood spiked with seven cell lines. The cell blocks and corresponding tumor tissues were immunostained with antibodies to seven markers: CK, EpCAM, EMA, CK18, AFP, Glypican 3 and HepPar1.

Continue Reading

Results from the BRISK-FL trial

fierce biotech

BRISK-FL Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Does Not Meet Overall Survival Primary Endpoint

(NYSE: BMY) today reported the result of the phase III BRISK-FL clinical trial of the investigational agent brivanib versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC; liver cancer). The study did not meet its primary overall survival objective based upon a non-inferiority statistical design.

BRISK-FL is a randomized, double-blind, multi-center phase III study of the investigational agent brivanib versus sorafenib in patients with advanced HCC who have not received prior systemic treatment. Bristol-Myers Squibb and the lead investigators plan to present the findings of the study at an upcoming scientific meeting.

Continue Reading

Sky Vegas review bettingy.com/sky-vegas-casino read at bettingy.com

Offcanvas Search

 x 
Cart - $0.00

  • Cart empty